ScienceGate
Advanced Search
Author Search
Journal Finder
Blog
Sign in / Sign up
ScienceGate
Search
Author Search
Journal Finder
Blog
Sign in / Sign up
Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study
British Journal of Haematology
◽
10.1111/bjh.15384
◽
2018
◽
Vol 182
(4)
◽
pp. 495-503
◽
Cited By ~ 17
Author(s):
Sundar Jagannath
◽
Jacob Laubach
◽
Ellice Wong
◽
Keith Stockerl-Goldstein
◽
Cara Rosenbaum
◽
...
Keyword(s):
Multiple Myeloma
◽
Phase 2
◽
Phase 2 Study
◽
Smouldering Multiple Myeloma
Download Full-text
Related Documents
Cited By
References
Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study
The Lancet Oncology
◽
10.1016/s1470-2045(19)30788-0
◽
2020
◽
Vol 21
(2)
◽
pp. 207-221
◽
Cited By ~ 72
Author(s):
Sagar Lonial
◽
Hans C Lee
◽
Ashraf Badros
◽
Suzanne Trudel
◽
Ajay K Nooka
◽
...
Keyword(s):
Multiple Myeloma
◽
Phase 2
◽
Open Label
◽
Refractory Multiple Myeloma
◽
Phase 2 Study
◽
Open Label Phase
Download Full-text
Initial Results of MCRN 009: Phase 2 Study of an Accelerated Infusion Rate of Daratumumab in Patients with Relapsed/Refractory Multiple Myeloma (MM).
Clinical Lymphoma Myeloma & Leukemia
◽
10.1016/j.clml.2019.09.428
◽
2019
◽
Vol 19
(10)
◽
pp. e259
Author(s):
Julie Stakiw
◽
Vishal Kukreti
◽
Richard LeBlanc
◽
Michael Sebag
◽
Annette Hay
◽
...
Keyword(s):
Multiple Myeloma
◽
Infusion Rate
◽
Phase 2
◽
Refractory Multiple Myeloma
◽
Phase 2 Study
◽
Initial Results
Download Full-text
Updated results of a phase 2 study of panobinostat combined with melphalan, thalidomide and prednisone (MPT) in relapsed/refractory multiple myeloma
Leukemia & Lymphoma
◽
10.1080/10428194.2017.1372575
◽
2017
◽
Vol 59
(5)
◽
pp. 1271-1273
◽
Cited By ~ 3
Author(s):
Massimo Offidani
◽
Laura Corvatta
◽
Anna Marina Liberati
◽
Stefano Pulini
◽
Stelvio Ballanti
◽
...
Keyword(s):
Multiple Myeloma
◽
Phase 2
◽
Refractory Multiple Myeloma
◽
Phase 2 Study
Download Full-text
Single-institute phase 2 study of thalidomide treatment for refractory or relapsed multiple myeloma: Prognostic factors and unique toxicity profile
Cancer Science
◽
10.1111/j.1349-7006.2008.00792.x
◽
2008
◽
Vol 99
(6)
◽
pp. 1243-1250
◽
Cited By ~ 12
Author(s):
Yutaka Hattori
◽
Shin-ichiro Okamoto
◽
Naoki Shimada
◽
Tsunayuki Kakimoto
◽
Kunihiko Morita
◽
...
Keyword(s):
Multiple Myeloma
◽
Prognostic Factors
◽
Toxicity Profile
◽
Phase 2
◽
Phase 2 Study
◽
Thalidomide Treatment
Download Full-text
PS1375 UPDATED SAFETY AND EFFICACY FROM A PHASE 2 STUDY OF VENETOCLAX PLUS CARFILZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
HemaSphere
◽
10.1097/01.hs9.0000563776.65272.b6
◽
2019
◽
Vol 3
(S1)
◽
pp. 629
◽
Cited By ~ 1
Author(s):
L. Costa
◽
E. Stadtmauer
◽
F. Davies
◽
G. Monohan
◽
T. Kovacsovics
◽
...
Keyword(s):
Multiple Myeloma
◽
Phase 2
◽
Safety And Efficacy
◽
Refractory Multiple Myeloma
◽
Phase 2 Study
Download Full-text
Elotuzumab plus lenalidomide and dexamethasone for newly diagnosed multiple myeloma: a randomized, open-label, phase 2 study in Japan
International Journal of Hematology
◽
10.1007/s12185-019-02757-0
◽
2019
◽
Vol 111
(1)
◽
pp. 65-74
◽
Cited By ~ 3
Author(s):
Kohmei Kubo
◽
Mitsuo Hori
◽
Kensuke Ohta
◽
Hiroshi Handa
◽
Kiyohiko Hatake
◽
...
Keyword(s):
Multiple Myeloma
◽
Phase 2
◽
Newly Diagnosed
◽
Open Label
◽
Phase 2 Study
◽
Open Label Phase
Download Full-text
Subcutaneous (SC) Daratumumab (DARA) in Combination With Standard Multiple Myeloma (MM) Treatment Regimens: An Open-label, Multicenter Phase 2 Study (PLEIADES)
Clinical Lymphoma Myeloma & Leukemia
◽
10.1016/j.clml.2019.09.023
◽
2019
◽
Vol 19
(10)
◽
pp. e16-e17
◽
Cited By ~ 4
Author(s):
Ajai Chari
◽
Hartmut Goldschmidt
◽
Jesus San-Miguel
◽
Helen McCarthy
◽
Kenshi Suzuki
◽
...
Keyword(s):
Multiple Myeloma
◽
Phase 2
◽
Open Label
◽
Treatment Regimens
◽
Multicenter Phase
◽
Phase 2 Study
Download Full-text
Phase 2 Study of Pegylated Liposomal Doxorubicin, Vincristine, Decreased-Frequency Dexamethasone, and Thalidomide in Newly Diagnosed and Relapsed-Refractory Multiple Myeloma
Mayo Clinic Proceedings
◽
10.4065/81.7.889
◽
2006
◽
Vol 81
(7)
◽
pp. 889-895
◽
Cited By ~ 85
Author(s):
Mohamad A. Hussein
◽
Rachid Baz
◽
Gordan Srkalovic
◽
Neeraj Agrawal
◽
Revathi Suppiah
◽
...
Keyword(s):
Multiple Myeloma
◽
Liposomal Doxorubicin
◽
Pegylated Liposomal Doxorubicin
◽
Phase 2
◽
Newly Diagnosed
◽
Refractory Multiple Myeloma
◽
Phase 2 Study
Download Full-text
Phase 2 Study of Pomalidomide (POM) + Low-Dose Dexamethasone (LoDEX) Following Second-Line Lenalidomide (LEN)-Based Treatment (Tx) in Patients (Pts) With Relapsed or Refractory Multiple Myeloma (RRMM): An Updated Analysis of Efficacy and Safety
Clinical Lymphoma Myeloma & Leukemia
◽
10.1016/j.clml.2017.03.255
◽
2017
◽
Vol 17
(1)
◽
pp. e141
Author(s):
David S. Siegel
◽
Gary J. Schiller
◽
Kevin Song
◽
Richy Agajanian
◽
Keith Stockerl-Goldstein
◽
...
Keyword(s):
Multiple Myeloma
◽
Low Dose
◽
Second Line
◽
Phase 2
◽
Efficacy And Safety
◽
Refractory Multiple Myeloma
◽
Phase 2 Study
Download Full-text
Vascular endothelial growth factor inhibition is not an effective therapeutic strategy for relapsed or refractory multiple myeloma: a phase 2 study of pazopanib (GW786034)
Blood
◽
10.1182/blood-2009-02-207209
◽
2009
◽
Vol 113
(19)
◽
pp. 4819-4820
◽
Cited By ~ 38
Author(s):
H. Miles Prince
◽
Dirk Hönemann
◽
Andrew Spencer
◽
David A. Rizzieri
◽
Edward A. Stadtmauer
◽
...
Keyword(s):
Multiple Myeloma
◽
Vascular Endothelial Growth Factor
◽
Growth Factor
◽
Therapeutic Strategy
◽
Vascular Endothelial
◽
Phase 2
◽
Refractory Multiple Myeloma
◽
Phase 2 Study
◽
Effective Therapeutic Strategy
◽
Endothelial Growth Factor
Download Full-text
Sign in / Sign up
Close
Export Citation Format
Close
Share Document
Close